Literature DB >> 18313840

Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.

Gihan Hosny1, Nahla Farahat, Hanan Tayel, Pierre Hainaut.   

Abstract

Circulating free DNA (CFDNA) has been shown to be a good source of liver tissue-derived DNA in African and Asian patients with chronic liver disease or HCC. In Egypt, HCC is a frequent carcinoma and mostly occur in the context of chronic infection by HCV, a widespread infection in the Egyptian population. Here we have examined the presence of mutations in TP53 at codon 249 (Ser-249, considered as a hallmark of mutagenesis by aflatoxin) and in CTNNB1 (gene encoding beta-catenin) in CFDNA of patients with HCC or chronic liver disease, from Alexandria, Egypt. The DNA concentrations were significantly higher in HCC patients compared to HBV and HCV carriers without cancer, and to sero-negative individuals. Ser-249 TP53 mutations were determined using PCR-restriction digestion (RFLP) in CFDNA of 255 subjects, and confirmed by sequencing. Ser-249 was found in CFDNA of 12 subjects (4.8%), with the highest prevalence in subjects with chronic liver disease and infection by HBV (6/36; 16.7%) Mutations in CTNNB1 were examined using PCR combined to DHPLC and followed by sequencing. No mutations were found in CTNNB1 neither in CFDNA or in tumour tissue. In parallel, studies on DNA extracted from 20 HCC biopsies showed the presence of ser-249 mutation in two cases (10%). These results indicate that mutagenesis by aflatoxin may play a role in hepatocarcinogenesis in Egypt, and CFDNA may serve as a convenient source of material in monitoring the effects of aflatoxin exposure and viral infections in chronic liver disease and cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313840     DOI: 10.1016/j.canlet.2008.01.031

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine.

Authors:  Selena Y Lin; Veerpal Dhillon; Surbhi Jain; Ting-Tsung Chang; Chi-Tan Hu; Yih-Jyh Lin; Shun-Hua Chen; Kung-Chao Chang; Wei Song; Lixin Yu; Timothy M Block; Ying-Hsiu Su
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

Review 2.  The clinical role of 'liquid biopsy' in hepatocellular carcinoma.

Authors:  Jessica A Howell; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-11-30

3.  Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.

Authors:  K L Aung; R E Board; G Ellison; E Donald; T Ward; G Clack; M Ranson; A Hughes; W Newman; C Dive
Journal:  Hugo J       Date:  2011-01-30

4.  The value of liquid biopsy in the diagnosis and staging of hepatocellular carcinoma: a systematic review.

Authors:  Poh Tan; Lisa Grundy; Peter Makary; Khem Hua Eng; George Ramsay; Mohamed Bekheit
Journal:  Transl Gastroenterol Hepatol       Date:  2021-10-25

Review 5.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

Review 6.  Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers.

Authors:  Chang-Qing Yin; Chun-Hui Yuan; Zhen Qu; Qing Guan; Hao Chen; Fu-Bing Wang
Journal:  Dis Markers       Date:  2016-06-15       Impact factor: 3.434

Review 7.  Biomarkers for Hepatocellular Carcinoma.

Authors:  Jiatao Lou; LingFei Zhang; Shaogang Lv; Chenzi Zhang; Shuai Jiang
Journal:  Biomark Cancer       Date:  2017-02-28

Review 8.  The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.

Authors:  Yahya I Elshimali; Husseina Khaddour; Marianna Sarkissyan; Yanyuan Wu; Jaydutt V Vadgama
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

Review 9.  Circulating tumor DNA in hepatocellular carcinoma: trends and challenges.

Authors:  Jia-Cheng Tang; Yi-Li Feng; Tao Guo; An-Yong Xie; Xiu-Jun Cai
Journal:  Cell Biosci       Date:  2016-05-11       Impact factor: 7.133

10.  Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity.

Authors:  Ao Huang; Xin Zhang; Shao-Lai Zhou; Ya Cao; Xiao-Wu Huang; Jia Fan; Xin-Rong Yang; Jian Zhou
Journal:  J Cancer       Date:  2016-09-13       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.